Drugs and Biologic Coverage Policy

Effective Date ........................................... 12/1/2020
Next Review Date ...................................... 12/1/2021
Coverage Policy Number .............................. 1021

Collagenase Clostridium Histolyticum

Table of Contents

Coverage Policy............................................. 1
FDA Approved Indications.............................. 2
Recommended Dosing .................................. 2
General Background ................................. 3
Coding/ Billing Information ......................... 4
References ................................................ 4

Related Coverage Resources

Male Sexual Dysfunction Treatment: Non-pharmacologic

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Coverage Policy

Collagenase clostridium histolyticum (Xiaflex®) is considered medically necessary when the following criteria are met:

- Age 18 years of age and older
- One of the following:
  - Treatment of a symptomatic Dupuytren’s contracture, when the following conditions are met:
    - Presence of a palpable cord
    - Functional impairment as manifested by a metacarpophalangeal (MCP) joint or proximal interphalangeal (PIP) joint contracture of 20 degrees of greater.
  - Treatment of Peyronie’s disease, when the following conditions are met:
    - Presence of a palpable plaque
    - EITHER of the following:
      - Curvature deformity between 30 degrees and 90 degrees at the start of therapy
      - Individual who has had an incomplete or partial course of Xiaflex injections and has a curvature deformity of at least 15 degrees (maximum is 8 injections in total)

Authorization for Xiaflex for Dupuytren’s contracture will be a maximum of three injections per cord.
Authorization for Xiaflex for Peyronie’s disease will be a maximum of 4 treatment cycles (or 8 injections).

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Collagenase clostridium histolyticum (Xiaflex®) is considered experimental, investigational or unproven for ANY other use including the following:

- Cosmetic uses
- Retreatment (i.e., treatment beyond three injections per affected cord for those with Dupuytren’s contracture or beyond eight injections for Peyronie’s disease):
  - For Dupuytren’s contracture, injections and finger extension procedures may be administered up to three times per cord. However, this does not limit treatment of additional cords.
  - For Peyronie’s disease, the safety of more than one treatment course (8 injections) is unknown.

Note: Receipt of sample product does not satisfy any criteria requirements for coverage.

**FDA Approved Indications**

**FDA Approved Indication**
Xiaflex is indicated for the treatment of adult patients with Dupuytren’s contracture with a palpable cord.

Xiaflex is indicated for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.

**Recommended Dosing**

**FDA Recommended Dosing**

**Dupuytren’s Contracture**
Xiaflex should be administered by a healthcare provider experienced in injection procedures of the hand and in the treatment of patients with Dupuytren’s contracture. The dose of Xiaflex is 0.58 mg per injection into a palpable cord with a contracture of a metacarpophalangeal (MP) joint or a proximal interphalangeal (PIP) joint. Approximately 24 to 72 hours after injection, perform a finger extension procedure if a contracture persists to facilitate cord disruption. Four weeks after the Xiaflex injection and finger extension procedure, if a MP or PIP contracture remains, the cord may be re-injected with a single dose of 0.58 mg of Xiaflex and the finger extension procedure may be repeated (approximately 24 to 72 hours after injection). Injections and finger extension procedures may be administered up to 3 times per cord at approximately 4-week intervals.

Perform up to two injections in the same hand during a treatment visit. Two palpable cords affecting two joints may be injected or one palpable cord affecting two joints in the same hand may be injected at two locations during a treatment visit. If a patient has other palpable cords with contractures of MP or PIP joints, these cords may be injected with Xiaflex at other treatment visits approximately 4 weeks apart.

Each vial of Xiaflex should only be used for a single injection. If two joints on the same hand are to be treated during a treatment visit, separate Xiaflex vials should be used for each injection.

**Peyronie’s Disease**
Xiaflex should be administered by a healthcare provider experienced in the treatment of male urological diseases, who has completed required training for use of Xiaflex in the treatment of Peyronie’s disease. The dose of Xiaflex is 0.58 mg per injection administered into a Peyronie’s plaque. If more than one plaque is present, inject into the plaque causing the curvature deformity.
A treatment course consists of a maximum of 4 treatment cycles. Each treatment cycle consists of two Xiaflex injection procedures and one penile modeling procedure. The second Xiaflex injection procedure is performed 1 to 3 days after the first. The penile modeling procedure is performed 1 to 3 days after the second injection of the treatment cycle. The interval between treatment cycles is approximately six weeks. The treatment course therefore, consists of a maximum of 8 injection procedures and 4 modeling procedures.

If the curvature deformity is less than 15 degrees after the first, second or third treatment cycle, or if the healthcare provider determines that further treatment is not clinically indicated, then the subsequent treatment cycles should not be administered.

The safety of more than one treatment course of Xiaflex is not known.

**Drug Availability**

Xiaflex is supplied in single-use vials containing 0.9 mg of collagenase clostridium histolyticum

**Xiaflex Risk Evaluation and Mitigation Strategy (REMS) Program**

Because of the risks of corporal rupture (penile fracture) or other serious penile injury in the treatment of Peyronie’s disease, Xiaflex is available only through the Xiaflex REMS Program. Required components of the Xiaflex REMS Program include the following:

- Prescribers must be certified with the program by enrolling and completing training in the administration of Xiaflex treatment for Peyronie’s disease.
- Healthcare sites must be certified with the program and ensure that Xiaflex is only dispensed for use by certified prescribers.

**General Background**

**OVERVIEW**

Xiaflex is a combination of bacterial collagenases indicated for the treatment of adult patients with Dupuytren’s contracture with a palpable cord, and for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.\(^1\)

Dupuytren’s contracture is a disorder of the palmar and digital fascia of the hand.\(^2\) Abnormal deposition of collagen initially causes nodules in the palm of the hand, which may thicken and lead to formation of cords. As the disease progresses, the cords gradually contract, leading to flexion deformities of the fingers. Joint contractures are typically painless but are associated with significant functional impairment. The exact etiology of Dupuytren’s contracture is unknown, although a number of risk factors have been reportedly associated with the condition, including alcohol, smoking, diabetes, epilepsy, thyroid disorders, and trauma. Prevalence varies widely by age and geographical location but is most common among Caucasian males greater than 50 years of age. Surgical intervention, either by open partial fasciectomy or percutaneous needle fasciotomy, is the mainstay of therapy for severe cases. However, surgery may be associated with complications including neurovascular injury or hematoma, and recurrence after surgery is common. In clinical studies of Dupuytren’s contracture, patients were eligible to participate if they had a finger contraction of 20 degrees to 100 degrees in a metacarpophalangeal (MP) joint or 20 degrees to 80 degrees in a proximal interphalangeal (PIP) joint.\(^1\)

Peyronie’s disease is an acquired penile abnormality caused by fibrosis of the tunica albuginea, which may lead to pain, deformity, erectile dysfunction, and/or distress.\(^3\) It is thought that repeated minor trauma to the penis initiates a cascade involving extravascular protein deposition, fibrin trapping, and overexpression of cytokines, leading to collagen changes characteristic of the condition. Males around 50 years of age are most commonly affected. Peyronie’s disease has a variable course; for most patients, pain will resolve over time without intervention, but curvature deformities are less likely to resolve without treatment. Intralesional therapy with Xiaflex may be used to treat curvature associated with Peyronie’s disease and is supported by American Urological Association guidelines (2015). In the pivotal studies, patients were required to have a penile deformity of at least 30 degrees.\(^1\) The safety of more than one treatment course (8 total injections) is unknown. At this time, there is insufficient published data in terms of safety and efficacy to support a treatment course beyond 8 injections for Peyronie’s disease.
Coding/ Billing Information

Covered when medically necessary:

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0775</td>
<td>Injection, collagenase clostridium histolyticum, 0.01 mg</td>
</tr>
</tbody>
</table>

Covered when medically necessary when used for the treatment of a symptomatic Dupuytren’s contracture in adults:

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20527</td>
<td>Injection, enzyme (eg, collagenase), palmar fascial cord, (ie, Dupuytren’s contracture)</td>
</tr>
<tr>
<td>26341</td>
<td>Manipulation, palmar fascial cord (ie, Dupuytren’s cord), post enzyme injection (eg, collagenase), single cord</td>
</tr>
<tr>
<td>29130</td>
<td>Application of finger splint; static</td>
</tr>
</tbody>
</table>

If coverage for the treatment of male sexual dysfunction, including erectile dysfunction, is available under the specific health benefit plan, the following may be covered when medically necessary:

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>54200</td>
<td>Injection procedure for Peyronie disease;</td>
</tr>
<tr>
<td>54235</td>
<td>Injection of corpora cavernosa with pharmacologic agent(s) (eg, papaverine, phentolamine)</td>
</tr>
</tbody>
</table>


References

1. Xiaflex® [prescribing information]. Malvern, PA: Endo Pharmaceuticals, Inc; June 2018.